Direct Meds GLP-1 Weight Loss Program Evaluated: LegitScript-Certified Compounded Semaglutide and Sublingual Access for Cash-Pay Patients in 2026

As cash-pay patients search for affordable compounded GLP-1 access in 2026, Direct Meds stands out for its active LegitScript certification, consistent pricing with no first-month introductory rate, and a sublingual needle-free format unavailable at most competing telehealth platforms.

WILMINGTON, DE, May 07, 2026 (GLOBE NEWSWIRE) --

DISCLAIMER: This article is for informational and educational purposes only and does not constitute medical advice. GLP-1 medications require evaluation and approval by a licensed healthcare provider. Compounded medications are not FDA-approved as finished drug products. This article contains affiliate links — if a purchase is made through links in this article, a commission may be earned at no additional cost to you. 

Direct Meds Program Overview:

Platform: Direct Meds

Category: Prescription Telehealth — Compounded GLP-1

LegitScript: Certified (active — verifiable at legitscript website)

FDA Warning Letters: None on record

Medications: Compounded semaglutide, compounded tirzepatide

Formats: Injectable and sublingual (needle-free drops)

Coverage: All 50 states (excluding Mississippi and Louisiana)

Insurance Required: No

HSA / FSA Accepted: Yes

Consultation: Included — no separate per-visit charge

Shipping: 1 business day from approval — free priority delivery

Provider Review: Within 6 hours of intake submission

Phone: (888) 696-7176

Official Website: directmeds.com

Direct Meds GLP-1 Program Evaluation

The compounded GLP-1 telehealth market in 2026 looks very different from where it stood 18 months ago.

The FDA issued warning letters to more than 30 platforms. Several programs paused operations. A major insurance coverage wave dropped GLP-1 coverage for an estimated 24 million Americans. And a new generation of cash-pay patients — people who were either previously insured or who discovered GLP-1 treatment for the first time — entered the market searching for an affordable, verifiably legitimate access point.

In this environment the question every patient should ask before choosing any compounded GLP-1 platform is the same: can I independently verify this platform's compliance credentials before I pay anything?

Direct Meds answers that question cleanly. It holds active LegitScript certification — verifiable in under 60 seconds at legitscript.com — has no FDA warning letters on record as of May 2026, offers the only sublingual needle-free GLP-1 format available at this price point in the current market, and operates with consistent pricing that does not spike after a promotional first month.

This evaluation covers everything a cash-pay patient needs to know before enrolling: how the program works, what it costs, which medications and formats are available, who qualifies, and what the realistic patient experience looks like from intake to results.

Patients who want to view the current Direct Meds program pricing and start their intake can do so here. The intake takes 10 to 15 minutes and a licensed provider reviews within 6 hours.

What is Direct Meds and Why Does LegitScript Certification Matter in 2026?

Direct Meds is a U.S.-based telehealth platform that connects patients with independent licensed healthcare providers for GLP-1 prescription evaluation through a fully online process. It is not a pharmacy and not a healthcare provider. It is the access layer between patients seeking medically supervised weight management support and the licensed clinicians who make all prescribing decisions based on individual patient evaluations.

The platform's compounding pharmacy partners are licensed U.S. compounding facilities that prepare medications according to the prescriptions they receive. According to the company, medications ship within one business day of prescription approval — with free priority delivery included and no pharmacy lines or pickup required.

What LegitScript Certification Actually Requires

LegitScript certification is not a self-reported badge. It is an independent third-party verification that requires a telehealth platform to demonstrate compliance with specific standards across four areas: licensed prescribing practices, pharmacy partnership verification, marketing accuracy, and operational transparency.

The certification is the same compliance framework used by Google, Meta, and major payment processors to screen telehealth platforms before allowing them to advertise or process payments. A platform that does not hold LegitScript certification cannot run paid advertising on most major digital platforms — which means LegitScript certification is both a compliance signal and a basic operational requirement for any serious GLP-1 telehealth business.

Direct Meds' active certification status is verifiable directly at legitscript.com by searching the domain directmeds.com. A confirmed result means the platform has been reviewed and approved under LegitScript's standards. Patients should perform this verification before enrolling in any compounded GLP-1 program — not just Direct Meds.

Semaglutide vs Tirzepatide — Which Does Direct Meds Offer and What Is the Difference?

Direct Meds offers both compounded semaglutide and compounded tirzepatide. Understanding the difference between these two active pharmaceutical ingredients helps patients have a more informed conversation with the reviewing provider during the intake process.

Semaglutide activates GLP-1 receptors only — the single-receptor mechanism that produced the STEP trial results. It is the active ingredient in Novo Nordisk's Wegovy (weight management indication) and Ozempic (diabetes indication). Semaglutide is administered once weekly via subcutaneous injection or as sublingual drops through Direct Meds' unique needle-free format. Clinical trial data shows average weight loss of approximately 15 percent of total body weight over 68 weeks.

Tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors — the dual-receptor mechanism that produced the SURMOUNT trial results. It is the active ingredient in Eli Lilly's Zepbound (weight management indication) and Mounjaro (diabetes indication). Head-to-head trial data comparing tirzepatide and semaglutide showed that tirzepatide produced significantly greater average weight loss under controlled study conditions — approximately 20 percent versus 15 percent for semaglutide at comparable timeframes. Tirzepatide is administered once weekly via subcutaneous injection through Direct Meds' injectable format.

The decision between semaglutide and tirzepatide is a clinical one made in consultation with the reviewing provider — not a consumer product selection. Patients who have previously been on semaglutide and achieved inadequate results, or who specifically want the dual-receptor mechanism, may discuss tirzepatide as an option during intake. Patients who are starting GLP-1 treatment for the first time and prefer a needle-free option should note that Direct Meds' sublingual format is currently available for semaglutide only.

How the Direct Meds Program Works — Complete Step-by-Step Process

The Direct Meds process is fully digital. No in-person visits. No scheduled video appointments. No insurance coordination required at any stage of the process.

Step 1 — The Online Health Intake

Patients visit the Direct Meds website and complete a detailed intake questionnaire covering medical history, current weight, height, goals, existing medications, and relevant health conditions. The intake takes approximately 10 to 15 minutes and is available 24 hours a day, 7 days a week — patients can complete it at any time without scheduling.

The intake questionnaire is specifically designed to collect the clinical information a licensed provider needs to evaluate GLP-1 eligibility — including BMI calculation, comorbidity documentation, contraindication screening, and previous weight management history. Patients transitioning from another GLP-1 platform should document their existing treatment history including current medication, dose, duration, and clinical response in the intake.

Step 2 — Licensed Provider Review Within 6 Hours

Once the intake is submitted, a licensed healthcare provider reviews the patient's information asynchronously — without requiring a scheduled video appointment or synchronous consultation. Direct Meds medical providers typically review every form within 6 hours.

The provider makes an independent clinical determination about whether a compounded GLP-1 prescription is appropriate for that specific patient based on the intake information. This determination is made entirely by the licensed clinician — not by Direct Meds' platform. Prescription approval is never guaranteed and rests entirely with the evaluating provider.

Step 3 — Approval, Payment, and Program Enrollment

If the provider determines a prescription is appropriate, the patient receives an approval notification and completes payment for their program. The consultation cost is included within the program pricing — there is no separate per-visit clinical fee added on top of the medication cost.

This all-in pricing structure means the figure a patient sees at enrollment is a true monthly cost — not a medication-only price that excludes clinical consultation fees billed separately. Patients can pay using credit cards, debit cards, HSA accounts, or FSA accounts.

Step 4 — Prescription Compounded and Shipped Within 1 Business Day

Once payment is received and the prescription is issued, it is sent to a licensed U.S. compounding pharmacy for preparation. According to Direct Meds, medications ship within one business day of prescription approval. Multiple patients have reported receiving their medication within 24 hours of prescription approval — making Direct Meds' shipping speed among the fastest in the compounded GLP-1 market.

Medications arrive in insulated mailers with cold packs to preserve temperature-sensitive compounds during transit. All supplies including needles and injection materials for the injectable format are included. No separate pharmacy trip or pickup is required.

Step 5 — Ongoing Care Through the Patient Portal

Once enrolled, all ongoing account activity — refills, dose adjustments, messaging with the care team, billing, and tracking — is managed through the Direct Meds patient portal. Licensed nurses are available throughout the treatment period for dosage questions, side effect management, and ongoing care guidance. No in-person visits, pharmacy pickups, or insurance reauthorizations are required at any point during the ongoing treatment relationship.

Dose adjustments are managed through the portal between monthly cycles. For patients who need to titrate to a higher maintenance dose — the standard clinical process for GLP-1 treatment — the adjustment request is reviewed by the licensed provider through the portal rather than requiring a new intake or a scheduled consultation. Click here for complete eligibility criteria and approval process!

Direct Meds Medication Options — Injectable and Sublingual Formats

The Injectable Format — Standard Compounded GLP-1 Access

The injectable format is the standard compounded GLP-1 delivery method across the telehealth market. Both compounded semaglutide and compounded tirzepatide are available in injectable format through Direct Meds — administered as once-weekly subcutaneous injections using the supplied materials.

Subcutaneous injection means the medication is injected into the fatty tissue just below the skin rather than into a muscle or vein. The injection sites — abdomen, upper thigh, or upper arm — are rotated weekly. The process is straightforward and most patients report that the injections become routine within the first two to three weeks of treatment.

For patients who are new to self-injection and concerned about the process Direct Meds' included nurse support provides guidance on proper technique, injection site rotation, and managing any local skin reactions that occasionally occur during the first weeks of treatment.

The Sublingual Format — Direct Meds' Unique Needle-Free Option

The sublingual format is the most distinctive feature of Direct Meds' medication offering — and the one that makes the platform meaningfully different from the majority of compounded GLP-1 telehealth providers currently operating.

Sublingual delivery involves placing liquid drops of compounded semaglutide under the tongue where they are absorbed through the sublingual mucosa — the mucous membrane beneath the tongue — directly into the bloodstream. No needle. No injection. No preparation of syringes or rotation of injection sites.

For the estimated 25 to 35 percent of prospective GLP-1 patients who cite needle aversion as a primary barrier to starting treatment this format is clinically meaningful. It removes the single most commonly cited objection to GLP-1 initiation without requiring a patient to choose between needle-based treatment and no treatment at all.

The sublingual format is available at the same program pricing as the injectable format — meaning patients do not pay a premium for the needle-free option. The medication is reviewed by the same licensed provider process, shipped in the same one-business-day timeline, and supported by the same nurse care team.

It is important to understand that the sublingual format is a compounded preparation and has not been studied through the same FDA-approved clinical trial process as injectable semaglutide formulations. Patients should discuss this distinction with their reviewing provider during the intake process.

Injectable vs Sublingual — Which Should You Choose?

The choice between injectable and sublingual delivery is ultimately a clinical and personal preference decision made in consultation with the reviewing provider. Here is the practical framework for thinking through it.

Injectable is typically appropriate for: Patients who are comfortable with self-injection and want the delivery method most directly consistent with the clinical trial protocols that established GLP-1 efficacy. Patients transitioning from branded injectable medications who want to continue the same administration method. Patients choosing tirzepatide — which is currently available in injectable format only through Direct Meds.

Sublingual is typically appropriate for: Patients with genuine needle aversion who have avoided starting GLP-1 treatment specifically because of the injection requirement. Patients who want a needle-free daily or weekly routine without the complexity of syringe preparation and injection site rotation. Patients who travel frequently and find injectable medication storage and transport inconvenient. Patients specifically choosing semaglutide — as the sublingual format is currently available for semaglutide only through Direct Meds.

Direct Meds Pricing — The Complete Cost Picture for Cash-Pay Patients

What Direct Meds Actually Charges — All-In Monthly Cost

Direct Meds' published pricing for compounded semaglutide and tirzepatide sits below the branded medication cash-pay floor — below LillyDirect's $299 per month entry for Zepbound and below NovoCare's cash-pay injectable semaglutide pricing.

The all-in monthly cost includes the medication, the provider consultation, nurse support, and free priority shipping. There are no separate per-visit clinical fees, no membership charges, and no annual prepayment required to access the standard pricing structure.

The pricing is consistent across the treatment period — the monthly cost a patient pays in month one is the same cost they pay in month six and month twelve. There is no promotional first-month introductory rate that spikes at the first refill — a pricing structure that has generated significant patient confusion at several competing platforms in the current market.

Patients should verify current program pricing directly at directmeds.com as promotional pricing and program structures are subject to change. The figures referenced in this report reflect publicly available pricing as of May 2026.

HSA and FSA Payment — Using Pre-Tax Dollars for GLP-1 Treatment

Direct Meds accepts HSA and FSA payments for all GLP-1 treatments. This is a meaningful practical benefit that most patients do not think to use when first enrolling.

GLP-1 medications prescribed by a licensed healthcare provider for the treatment of a qualifying medical condition — including obesity, type 2 diabetes, cardiovascular risk factors, and obstructive sleep apnea — are eligible medical expenses under Health Savings Accounts and Flexible Spending Accounts under IRS guidelines.

For patients with HSA balances — which roll over year to year — the existing pre-tax balance can be applied to Direct Meds program costs at any time. For patients with FSA balances — which typically expire at the end of the plan year under use-it-or-lose-it rules — the Q4 window between October and December is an optimal time to apply expiring FSA funds to GLP-1 treatment costs rather than forfeiting them.

A patient with a $2,400 FSA balance remaining in October who applies it to Direct Meds compounded GLP-1 treatment converts pre-tax dollars that would otherwise be forfeited into multiple months of continued treatment. Once approved, Direct Meds provides receipts and documentation for HSA or FSA reimbursement.

Direct Meds for Patients Who Lost Insurance Coverage in 2026

The practical advantages of Direct Meds specifically for coverage-loss patients:

Speed: The 6-hour provider review and 1-business-day shipping timeline means patients who discover their coverage has been dropped can have a replacement compounded prescription at their door within 3 to 5 days — fast enough to prevent a treatment gap in most cases.

No previous prescription required: Direct Meds licensed providers can issue a new compounded prescription based on their own clinical evaluation — patients do not need to transfer a prescription from their previous provider.

Dose continuity: Patients transitioning from branded medications should document their current medication and current dose in the Direct Meds intake. The reviewing provider will factor this treatment history into the compounded prescription — meaning patients do not typically need to restart titration from the beginning when transitioning from branded to compounded access.

HSA and FSA bridging: Patients with remaining HSA or FSA balances can apply pre-tax funds to Direct Meds costs immediately — using existing pre-tax health account assets during the coverage gap period.

Patients who lost insurance coverage and want to explore Direct Meds as a continuation pathway can view current program details and start their intake here.

Who Qualifies for Direct Meds GLP-1 Treatment

BMI and Clinical Eligibility Criteria

To qualify for GLP-1 treatment through Direct Meds, patients generally need to meet one of the following BMI-based criteria:

A BMI of 30 or above — the standard clinical classification for obesity — without any additional qualifying condition requirement.

Or a BMI of 27 or above — classified as overweight — combined with at least one weight-related comorbidity. Qualifying comorbidities include hypertension, type 2 diabetes, obstructive sleep apnea, cardiovascular disease, or dyslipidemia.

These are the same eligibility criteria embedded in the FDA-approved indications for semaglutide and tirzepatide for chronic weight management. They are not Direct Meds-specific thresholds — they reflect the clinical standards applied by any compliant GLP-1 prescribing program.

Patients with a BMI below 27 are not typically eligible for GLP-1 treatment for weight management through any provider operating within FDA-approved prescribing guidelines.

Conditions That May Strengthen Your Eligibility Case

Patients with any of the following conditions should document them clearly in the intake questionnaire — because each represents a weight-related comorbidity that strengthens the medical necessity argument for GLP-1 treatment:

High blood pressure (hypertension) is one of the most common qualifying comorbidities. GLP-1 medications have demonstrated cardiovascular benefits beyond weight loss alone in clinical trials — making hypertensive patients with elevated BMI a well-supported candidate population.

Type 2 diabetes or prediabetes is another strong qualifying condition. Semaglutide was originally developed and approved for type 2 diabetes management before its weight loss applications were recognized. Patients with type 2 diabetes and elevated BMI are among the most clinically well-supported candidates for GLP-1 treatment.

Obstructive sleep apnea — particularly relevant given the FDA's December 2024 approval of tirzepatide specifically for obesity-related OSA — also qualifies as a relevant comorbidity for patients in the BMI 27 to 29.9 range.

Absolute Contraindications — Who Cannot Use GLP-1 Medications

Certain medical conditions are absolute contraindications for GLP-1 medications regardless of BMI or other clinical factors.

A personal or family history of medullary thyroid carcinoma is the most prominent contraindication. GLP-1 receptor agonists carry an FDA black box warning regarding potential thyroid C-cell tumor risk based on animal study data.

Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) carries the same contraindication.

Severe inflammatory bowel disease including active Crohn's disease or ulcerative colitis, and gastroparesis — a condition that causes delayed stomach emptying — are conditions that typically preclude GLP-1 treatment because the medications further slow gastric emptying.

A history of pancreatitis is also evaluated carefully as GLP-1 medications have been associated with increased pancreatitis risk in post-market surveillance data.

Direct Meds' intake questionnaire is designed to screen for these contraindications. Patients with any of these conditions should document them openly in their intake rather than attempting to navigate around the screening — both for safety reasons and because a provider who identifies an undisclosed contraindication will decline to prescribe regardless.

Geographic Coverage and State Restrictions

Direct Meds provides services in all U.S. states except Mississippi and Louisiana where telehealth prescription of weight loss medications is currently prohibited under state law. Patients in these two states are not eligible for Direct Meds' GLP-1 programs regardless of clinical eligibility.

For patients in all other 48 states plus Washington D.C. the service is available at the same pricing, same intake process, and same delivery timeline with no geographic variation in program terms.

Direct Meds and the 2026 Insurance Coverage Loss Landscape

Why 24 Million Americans Are Searching for GLP-1 Like Direct Meds Right Now

Between 2025 and 2026 an estimated 24 million Americans lost insurance coverage for GLP-1 medications — as major pharmacy benefit managers dropped GLP-1s from their formularies and employers restructured health benefits to manage pharmacy cost growth.

Patients caught in this coverage loss are not simply disappointed. Many of them are in the middle of active GLP-1 treatment — they have lost weight, experienced metabolic improvements, and are facing the prospect of their progress reversing if they cannot find an affordable continuation pathway before their current supply runs out.

Why Direct Meds Is Specifically Well-Positioned for Coverage-Loss Patients

Direct Meds' combination of features makes it particularly well-suited for the coverage-loss patient population in a way that most competing platforms are not simultaneously.

The 6-hour provider review means patients who discover their coverage has been dropped on a Monday can have a replacement prescription approved and shipping by Tuesday — preventing the treatment gap that causes rapid weight regain in the first two to four weeks of discontinuation.

The new prescription capability means patients do not need to navigate a prior authorization transfer from their previous branded provider. The Direct Meds provider evaluates the patient's health intake — including their documented treatment history from their previous program — and issues a new compounded prescription based on that clinical assessment.

The compounded pricing below the branded cash-pay floor means patients who were previously paying a modest insurance copay can continue treatment at an out-of-pocket cost substantially below what branded cash-pay access through LillyDirect or NovoCare would cost.

And the HSA and FSA acceptance means patients with remaining pre-tax health account balances can bridge the coverage gap period using existing pre-tax assets — reducing or eliminating the net out-of-pocket cost during the period when the insurance appeal is being pursued in parallel.

Frequently Asked Questions — Complete

Is Direct Meds a Legitimate Platform?

Direct Meds holds active LegitScript certification verifiable at legitscript.com and has no FDA warning letters on record as of May 2026. It operates as a licensed telehealth platform connecting patients with independent licensed healthcare providers. All prescribing decisions are made by licensed clinicians — not by the Direct Meds platform itself.

How Long Does the Direct Meds Approval Process Take?

Direct Meds medical providers typically review every intake form within 6 hours. No video appointment or scheduled consultation is required. The entire process from completing the intake to receiving an approval or denial notification typically occurs within the same business day.

Is Compounded Semaglutide the Same as Wegovy?

Compounded semaglutide uses the same active pharmaceutical ingredient — semaglutide — as Wegovy and Ozempic but is not the same FDA-approved finished drug product. The pharmacological active ingredient is identical. The regulatory oversight of the manufacturing process and finished product quality control is different. Patients should discuss this distinction clearly with their reviewing provider before starting compounded treatment.

What Is the Sublingual GLP-1 Option and Who Is It For?

The sublingual format delivers compounded semaglutide as liquid drops placed under the tongue — providing needle-free GLP-1 access for patients who want to avoid self-injection. It is available at the same program pricing as the injectable format and reviewed through the same licensed provider process. The sublingual format is a compounded preparation and has not been studied through the same FDA-approved clinical trial process as injectable semaglutide.

Can Direct Meds Issue a New GLP-1 Prescription?

Yes. Direct Meds licensed providers evaluate new patients and can issue new GLP-1 prescriptions based on their clinical assessment of the intake. The platform is not exclusively a renewal service for patients with existing prescriptions — new patients who have never been on GLP-1 treatment can receive a new prescription through the standard intake process.

Does Direct Meds Accept HSA and FSA Payments?

Yes. Direct Meds accepts HSA and FSA payments for all GLP-1 treatment programs and provides receipts and documentation for reimbursement as needed.

What States Does Direct Meds Serve?

Direct Meds serves patients in all U.S. states except Mississippi and Louisiana where telehealth prescription of weight loss medications is prohibited under state law.

How Does Direct Meds Handle Dose Adjustments?

Dose adjustments during active titration are managed through the patient portal. Patients communicate adjustment requests to their care team through the portal and the licensed provider reviews and issues the updated prescription. No new intake, scheduled consultation, or in-person visit is required for dose adjustment.

What Happens If I Am Not Approved?

Prescription approval is not guaranteed. The reviewing clinician makes an independent determination based on each patient's individual health intake — including BMI, medical history, comorbidities, and contraindication screening. If a patient is not approved the clinical determination rests with the licensed provider. Patients who are not approved may be advised to pursue GLP-1 treatment through a different access pathway that better accommodates their clinical situation.

Can I Switch to Direct Meds From Another GLP-1 Platform?

Yes. Patients transitioning from any other compounded GLP-1 platform should document their current medication, current weekly dose, duration at that dose, and clinical response in the Direct Meds intake questionnaire. The reviewing provider will factor this history into the prescribing decision — typically prescribing the compounded formulation at the same dose the patient was taking at their previous platform rather than restarting titration from the beginning.

Is There a Money-Back Guarantee?

Patients should verify current refund and cancellation terms directly at directmeds.com before enrolling. Direct Meds operates on a subscription model and patients should understand the subscription structure, billing cycle, and cancellation process before completing enrollment — as the cancellation process is phone-based rather than portal-based according to some patient reviews.

Direct Meds is available exclusively through the official website at directmeds.com. View the current program details, check eligibility, and start the intake process here. The intake takes 10 to 15 minutes, a licensed provider reviews within 6 hours, and approved prescriptions ship within 1 business day.

About Direct Meds

Direct Meds is a LegitScript-certified telehealth platform dedicated to connecting patients with independent licensed healthcare providers across the United States. The platform facilitates access to virtual medical consultations and, where clinically appropriate, prescription medications through a streamlined online process — with prescriptions fulfilled through licensed pharmacy partners and shipped directly to patients.

Direct Meds does not practice medicine and does not prescribe medications. All prescribing decisions are made exclusively by independent licensed clinicians who evaluate each patient individually based on their medical history, health goals, and clinical eligibility. Prescription approval is not guaranteed.

Email: help@directmeds.com Phone: (888) 696-7176 Hours: 9:00 AM – 9:00 PM EST, Daily

Medical Disclaimer: This article is for informational and educational purposes only. Nothing in this article constitutes medical advice. GLP-1 receptor agonist medications are prescription medications requiring evaluation by a licensed healthcare provider. Do not start, stop, or modify any medication without consulting your provider.

Affiliate Disclosure: This article contains affiliate links. Links to Direct Meds may be affiliate links through which a commission is earned if a reader completes a qualifying enrollment. This does not increase the cost to the consumer and does not influence the factual accuracy of the information presented.

Compounded Medication Disclaimer: Compounded semaglutide and compounded tirzepatide are not FDA-approved as finished drug products. The FDA does not review compounded medications for safety, effectiveness, or quality prior to dispensing. All compounded medications are dispensed under licensed provider prescriptions through licensed compounding pharmacies.

Brand Disclaimer: Wegovy®, Ozempic®, Zepbound®, Mounjaro®, LegitScript® are registered trademarks of their respective owners. Referenced for informational purposes only.

Pricing Notice: All pricing figures reflect conditions as of May 2026 and are subject to change. Verify current pricing directly at directmeds.com before enrolling.

Attachment

• Direct Meds

Email: help@directmeds.com Phone: (888) 696-7176 Hours: 9:00 AM – 9:00 PM EST, Daily

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.